archers at the University of Utah School of Medicine reported results from a follow-up to an earlier glucosamine trial. Arthritis patients in this leg of the study took glucosamine; a combination of glucosamine and chondroitin; the anti-inflammatory drug celecoxib (Celebrex), or a placebo. X-rays were taken of patients' knees before the trial began and one and two years later to determine whether glucosamine alone, or in combination with chondroitin, would slow the loss of cartilage.
Lead author Dr. Allen D. Sawitzke, an associate professor of internal medicine at the University of Utah School of Medicine, said he and his colleagues had hoped to have enough patients and measurement accuracy to be able to show some slowing of the damage, but in the end, the results were inconclusive.
"So, it's an example of a null study, that is, a study where there is no difference detected, which isn't the same as saying there is no difference," Sawitzke said.
Dr. Jason Theodosakis, an assistant professor at the University of Arizona College of Medicine and author of the book, The Arthritis Cure, said the study was flawed in many ways, including the small sample size, short duration and imprecise X-ray methodology. "I really can't believe it was even published," he said.
Like many physicians, Theodosakis continues to recommend glucosamine and chondroitin. "This study does nothing to discourage that," he said.
Trying glucosamine for 60 days makes sense, especially for patients who can't tolerate ibuprofen or other nonsteroidal anti-inflammatory drugs, said Dr. Stephen Dahmer, a former fellow in integrative medicine at Beth Israel Medical Center in New York City, and now a staff physician at the VA San Diego Medical Center.
Sawitzke said he sees some merit in the supplement for pain relief, but there's a lot less evidence to support glucosamine as a way to slow cartilage damage.
Vlad, however, tells patien
Page: 1 2 3 Related medicine news :1
All rights reserved
. Skin color studies on tadpoles lead to cancer advance2
. Nuvo Research Announces Successful Completion Of All Pennsaid(R) Studies3
. Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients4
. American Heart Association 2008 Wrap-Up Report: Top Research Advances Include Studies That Influence Medical Care, Apply Science To Real World Communities5
. Zebrafish Journal Publishes Skin Pigmentation Studies That Shed Light on the Evolution of Race6
. Diabetes and Cardiovascular Disease: Online Presentation Looks at the Complex Relationship of These Two Diseases in Light of Recent Studies7
. Studies Challenge Framingham Risk Score8
. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.9
. Eating More Fish a Wise New Year Resolution, Studies Show10
. Studies on Smoking Genes and Transcriptional Control of Chronic Fatigue Syndrome Revealed in Molecular Medicine 11
. Rockefeller Universitys Center for Clinical and Translational Science funds 18 new pilot studies